Fulcrum Therapeutics Inc

Fulcrum Therapeutics’ Phase 1b pociredir trial shows 20 mg boosts hemoglobin and reduces vaso‑occlusive crises in sickle cell disease—early evidence of a promising gene‑regulation therapy.

Fulcrum Therapeutics Inc. has made significant progress in treating sickle cell disease with its gene regulation drug pociredir, showing promising results in a Phase 1b trial and maintaining a strong financial position.

Fulcrum Therapeutics, Inc. is a pioneering biotech company that is revolutionizing the treatment of diseases through innovative gene regulation techniques, with a strong focus on collaboration and patient-centric solutions.

Fulcrum Therapeutics is a Cambridge-based biotech company focused on developing innovative gene regulation therapies to address various diseases.

Fulcrum Therapeutics is a pioneering force in gene regulation, with promising clinical trial progress and a strong financial foundation, positioning it as a beacon of hope for treating genetic diseases.

Fulcrum Therapeutics Inc. is navigating a challenging financial landscape amidst promising clinical developments, with investors weighing the potential for future profitability against current losses.

Fulcrum Therapeutics has announced a conference call for May 1, 2025, to discuss its Q1 2025 financial results and provide insights into its strategic direction and future plans.